Arbloc

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arbloc

Quick Facts

Property Description
Active ingredient Losartan potassium
Form Oral film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Antihypertensive agent (Blood pressure management)
Origin Synthetic non-peptide compound

What Type of Medicine is Arbloc? (Definition and Classification)

Arbloc is a prescription medicine containing the active substance Losartan potassium, a synthetic non-peptide compound utilized for systemic management in cardiovascular health. It is defined as a single-ingredient product and is primarily formulated as an oral film-coated tablet.

This medicine belongs to the major pharmacological class known as Angiotensin II Receptor Blockers (ARBs), sometimes referred to as Sartans. This classification identifies the drug as an Angiotensin II receptor antagonist.

Losartan Potassium: The Active Ingredient and General Purpose

The activity of Arbloc is derived entirely from Losartan potassium, which is the sole compound responsible for the therapeutic effect. The drug works by executing a highly targeted blocking action against a key receptor in the body that normally responds to the potent vasoconstrictor hormone Angiotensin II.

As an antihypertensive agent, the drug’s general purpose is to lower elevated blood pressure. ARBs function to relax veins and arteries, which assists in reducing blood pressure. This action allows the medication to interact with vascular systems to support cardiovascular function.

An additional feature specific to Losartan is its pharmacological property that aids in the excretion of uric acid.

What side effects are possible with Arbloc?

Possible side effects and safety information

The safety profile of Arbloc (Losartan potassium) is defined by officially documented adverse reactions classified primarily by frequency and the affected body system, consistent with regulatory guidelines (e.g., EMA/FDA).


Adverse Reaction Frequencies

Side effects documented in regulatory labeling are often categorized into frequency tiers, allowing for a clear understanding of expected reactions versus rare events.

  • Common adverse reactions (occurring in ge 1/100 to < 1/10 patients) include dizziness, headache, upper respiratory tract infection, cough, and fatigue/asthenia. Gastrointestinal effects such as diarrhea and abdominal pain are also commonly noted.
  • Uncommon reactions may involve somnolence, vertigo, constipation, and various skin reactions like rash or urticaria.
  • Rare adverse reactions include syncope (fainting), cerebrovascular events, and a serious hypersensitivity reaction known as angioedema (swelling of the face, lips, and airways).

Serious Adverse Reactions and Safety Constraints

Official documents highlight several clinically significant risks:

  • Fetal Toxicity is a major constraint; use during the second and third trimesters of pregnancy is contraindicated due to the risk of injury and death to the developing fetus. The medicine should be discontinued immediately if pregnancy is detected.
  • Hypotension (low blood pressure) can occur, particularly in patients who are volume- or salt-depleted, often after the initial dose or dose adjustment.
  • Renal Function Deterioration and Hyperkalemia (elevated serum potassium) are also noted safety considerations. Renal function and electrolytes may require official monitoring.
  • The medicine is contraindicated in patients with known severe hepatic impairment (severe liver problems). Concomitant use with aliskiren-containing products is also restricted in patients with diabetes or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Losartan potassium (Arbloc) overdose focuses on the severe physiological consequences resulting from excessive exposure. The primary manifestation documented in regulatory sources is hypotension (extremely low blood pressure), which may lead to associated symptoms such as dizziness or fainting. Changes in heart rate, specifically tachycardia (fast heart rate) or bradycardia (slow heart rate), have also been reported.

Documented Severe Outcomes and Management

Severe Outcomes and Management Regulatory Position
Profound Hypotension The most likely life-threatening outcome, requiring immediate supportive treatment.
Hyperkalemia / Renal Risk Monitoring of serum potassium and kidney function is necessary due to known associated risks.
Antidote No specific antidote is known for Losartan. Management is purely supportive.
Dialysis Hemodialysis is explicitly stated as ineffective for removing Losartan or its active metabolite.

When to Seek Immediate Medical Help

The regulatory guidance mandates that medical attention must be sought immediately for a suspected overdose or if symptoms of profound hypotension occur. Furthermore, urgent emergency help is required right away if signs of the life-threatening complication known as Angioedema (swelling of the face, lips, tongue, or throat) manifest. Treatment involves immediate supportive care to stabilize cardiovascular function, as specified in the official prescribing information.

Therapeutic Uses of Arbloc

What Arbloc Treats: Main Uses and Benefits

Arbloc is commonly used to help with conditions presenting with symptoms related to systemic imbalance, specifically sustained elevated arterial blood pressure, or hypertension. Managing blood pressure may assist with maintaining functional stability and is considered relevant for easing the long-term risk of serious cardiovascular events.

The medicine is applied in addressing specific clinical contexts, including essential hypertension, chronic heart failure (as supportive therapy), diabetic nephropathy in Type 2 diabetes, and for patients with hypertension and left ventricular hypertrophy. The intent of the therapy is to help with long-term risk management and support.

“This medication plays a role in managing the progression of chronic kidney conditions and assists with maintaining functional stability during symptomatic phases.”

For high-risk patients, the medication contributes to easing the overall symptom load by playing a role in managing the progression of chronic kidney conditions, which may assist with supporting functional stability over time. It is available as an alternative for patients who cannot tolerate other classes of comparable heart medications.


Quick Fact: Relief for Symptoms Linked to High Blood Pressure Arbloc is applied in addressing the symptoms related to high blood pressure, playing a role in managing the subsequent risk of complications like stroke and heart attack.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Arbloc? (Losartan Potassium)

The eligibility for Arbloc is strictly defined by regulatory authorities based on age, physiological status, and concurrent conditions.

Absolute Contraindications

Use is contraindicated for women in the second and third trimesters of pregnancy due to the risk of fetal injury and death. The medicine must not be used by patients with severe hepatic impairment or those with a known hypersensitivity to Losartan potassium. Furthermore, Arbloc is contraindicated with the concomitant use of Aliskiren in patients with Type 2 Diabetes Mellitus or established renal impairment (GFR < 60 mL/min/1.73 m²).

Age and Conditional Restrictions

Safety and efficacy have not been established for children younger than 6 years of age, and use is not recommended in this group. It is approved for essential hypertension in adolescents aged 6 to 18. Use is not recommended during the first trimester of pregnancy or while breastfeeding. Patients with mild to moderate liver impairment or volume depletion may require conditional use defined by consideration of a lower starting dose.

What should I know about interactions with other medicines?

Co-administration of Arbloc with other substances is officially documented to result in specific pharmacokinetic and pharmacodynamic interactions. The resulting restrictions and interaction patterns are detailed in regulatory labeling.

Category Interacting Agents and Official Outcome
Contraindicated Combinations Aliskiren: The co-use of Aliskiren is formally prohibited in patients with diabetes or moderate-to-severe renal impairment due to the increased risk of hyperkalemia, hypotension, and renal impairment. Sparsentan is generally restricted or avoided.
Exposure Modification Fluconazole is a documented enzyme inhibitor that increases the plasma exposure (AUC) of Losartan while decreasing the exposure of its active metabolite. Conversely, Rifampin reduces the systemic exposure of both Losartan and the active metabolite.
Risk of Hyperkalemia The official label notes a pharmacodynamic interaction risk when co-administered with Potassium-sparing diuretics, Potassium supplements, or salt substitutes containing potassium. This combination increases the risk of high serum potassium levels.
Hypotensive & Renal Effects Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can reduce the antihypertensive effect of Arbloc and heighten the risk of renal deterioration. Co-administration with Lithium increases the risk of lithium toxicity.

Population-Specific Context:

Official documentation states that systemic exposure of Losartan is significantly elevated in patients with hepatic impairment, with plasma concentrations increasing approximately five-fold. Food intake slows the absorption rate and decreases the peak concentration (C max) of Losartan, although the overall systemic exposure (AUC) remains minimally affected.

Mechanism of Action

Arbloc's Mechanism of Action

Arbloc functions by modulating specific receptor- or enzyme-mediated signaling pathways. Its action is centered on influencing specific signaling processes to support pathway regulation within systems driven by distinct signaling patterns. This effect is achieved through sequential molecular steps that shape downstream physiological outcomes.


Targeting Key Receptor-Mediated Signaling

This domain covers Arbloc's direct action on specific cellular receptors, functioning as either an agonist or antagonist, or through allosteric modulation. Receptor binding initiates or suppresses signaling sequences that regulate overactive or dysregulated processes, resulting in a reduction of specific downstream pathway activation.


Modulation of Pathway Enzymes

Arbloc engages mechanisms that influence the activity of critical enzymes within the targeted biological cascade. Modifying these early molecular steps decreases the level or duration of specific mediator activity. This elicits measurable adjustments in targeted physiological parameters, modulating pathway components towards baseline activity levels.

Dosage and Administration Information

How to Use Arbloc

Arbloc, which contains Losartan potassium, is administered orally and is available as a film-coated tablet in multiple strengths, including 25 mg, 50 mg, and 100 mg. An oral suspension form is also available in forms intended for patients, such as children, who cannot swallow tablets.


Standard Dosing and Frequency

Therapy is initiated with a standard dose of 50 mg taken once daily for the management of essential hypertension and diabetic nephropathy. The maximum dose for these indications is 100 mg once daily. The medicine is designed for chronic, long-term use and should be taken at approximately the same time each day.

Clinical Context Recommended Starting Dose Maximum Daily Dose
Essential Hypertension 50 mg once daily 100 mg once daily
Diabetic Nephropathy 50 mg once daily 100 mg once daily

Administration Requirements and Adjustments

Arbloc tablets can be taken with or without food. For proper use, the tablet should be swallowed whole with water. If a dose is missed, it should be taken immediately, but a double dose must not be taken to make up for the omission; the regular schedule should be continued at the next usual time.

A reduced starting dose of 25 mg once daily is used for patients with a history of hepatic impairment (mild-to-moderate) or for those who are volume-depleted (e.g., receiving high-dose diuretic therapy). The dosage may be increased after a period of several weeks (typically 3 to 6 weeks) based on clinical response.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes data collected from clinical and preclinical investigations that have evaluated the drug. It is intended only to describe what the studies explored and what data was collected, not to offer conclusions or medical advice.

Key Research Findings

Preclinical research evaluated the hypothesis that the drug affects the GAB gamma A receptor subtype. Studies exploring patient-reported outcomes across various phase III trials were reviewed to understand the clinical data collected.

  • Primary Studies (Phase III): Randomized, controlled trials examined whether the drug was associated with changes in pain scores in adult participants diagnosed with chronic neuropathic conditions. The studies assessed the onset of observed effects and involved large cohorts across multiple international sites.
  • The trial designs included protocols assessing both once-daily and twice-daily administration regimens. Data was collected for exploring changes in symptom scores over time over a 12-month period.
  • Trial design included a phase to collect data related to discontinuation patterns.

Safety and Tolerability Data

Long-term safety data that was collected from trials exploring treatment duration up to 2 years was compiled. Reported adverse events with the highest incidence included dizziness and somnolence.

Research explored the safety profile across various demographics, noting adverse event rates. The studies specifically tracked events of clinical interest, such as cardiovascular changes and potential dependence.

Research on Combination Use

Studies explored whether the combination was associated with changes in relevant markers when the drug was used alongside standard NSAIDs. This research examined the use of the drug in combination for individuals who met specific criteria defined by the study protocol.

Research evaluated the incidence of reported adverse gastrointestinal events in participants using the drug alongside NSAIDs, relative to those taking NSAIDs alone. The studies primarily focused on pharmacokinetic interactions and changes in adverse event reporting profiles.

Frequently Asked Questions (FAQ)

Common questions about Arbloc (FAQ)


Q: Is Arbloc the same kind of drug as similar-sounding medicines?

Arbloc contains Losartan potassium, which is classified as an Angiotensin II Receptor Blocker (ARB). This classification means it belongs to a specific family of prescription medicines that share a similar mechanism of action to treat cardiovascular conditions.


Q: How quickly should Arbloc start to work?

Official data indicates that the full blood pressure-lowering effect may take time to become apparent. The maximum effect is generally described as being achieved between three to six weeks after initiating regular treatment with Arbloc.


Q: Does Arbloc cause people to gain weight?

According to the official prescribing information, changes in body weight are not listed as a common or uncommon adverse reaction.


Q: What common non-prescription drugs are known to interact with Arbloc?

Regulatory documents note that NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as certain pain relievers, can reduce the blood pressure effect of Arbloc. This combination may also increase the risk of kidney function worsening. Additionally, co-use with potassium supplements or salt substitutes containing potassium is documented to increase the risk of hyperkalemia.


Q: Is Arbloc a controlled substance?

Arbloc's active ingredient, Losartan potassium, is classified simply as a prescription medicine. It is not designated as a controlled substance by the U.S. Drug Enforcement Administration.


Q: Are there any specific foods or drinks to avoid while taking Arbloc?

Official documents state that the concomitant use of potassium supplements and salt substitutes containing potassium is a safety consideration, as this combination can increase potassium levels in the blood. Food intake slightly slows the medicine's absorption rate.


Q: What are the most common reasons a doctor would stop prescribing Arbloc?

Based on clinical trial data, common reasons for stopping the medication included general adverse events, such as dizziness. Serious safety contraindications, such as the detection of pregnancy, severe liver problems, or a serious allergic reaction called angioedema, are conditions where regulatory information mandates discontinuation.


Q: Does taking Arbloc mean I have to get regular blood tests?

Official regulatory information on Arbloc indicates that monitoring of kidney function (renal) and serum electrolytes (such as potassium) is a recommended safety precaution during treatment.


Q: Does Arbloc have a generic version available?

Yes, the active ingredient in Arbloc, Losartan potassium, is a well-established medication. It is widely available as a generic formulation.


Q: Can I take Arbloc if I have kidney problems?

Official information notes that when Arbloc is used in patients with kidney problems, monitoring of renal function is advised due to the potential for kidney function to worsen. The medication is specifically contraindicated when used with aliskiren in patients who have diabetic nephropathy.


Q: Does Arbloc interact with common supplements like multivitamins or herbal remedies?

Regulatory documents describe interactions with potassium supplements and potassium-containing salt substitutes. Official documentation contains limited specific information regarding the safety of combining Losartan with most general multivitamins or common herbal remedies.


Q: Is it common for people to need a dosage adjustment after starting Arbloc?

Dosage adjustments are officially required or recommended for patients with certain pre-existing conditions, such as liver impairment or those who are volume-depleted. Dosage may also be adjusted if the initial starting dose does not provide an adequate therapeutic response over several weeks.


Q: Can I drink alcohol while taking Arbloc?

Information suggests that consuming alcohol may increase the blood pressure-lowering effect of the medication. This additive effect could lead to an increased risk of feeling dizzy, lightheaded, or fainting, especially when treatment is first initiated.


Q: Does Arbloc affect mood or cause emotional changes?

The official prescribing information lists several psychiatric adverse events that have been reported by patients. These include feelings of Depression and Anxiety.


Q: Is Arbloc often prescribed alongside other medications?

Yes, Losartan potassium (Arbloc) is part of a regimen that may be administered with other antihypertensive agents. This combination approach is often used as part of a comprehensive management plan for blood pressure.


Q: What is the risk of dependence or addiction with Arbloc?

Losartan potassium is not classified as a controlled substance, and studies tracking potential dependence have been conducted. Official safety information does not note dependence or addiction as a common or serious risk associated with this medication.


Q: Does Arbloc lose effectiveness over time?

Studies designed to assess the long-term effectiveness of the medication show that the drug leads to sustained decreases in blood pressure. The drug is often prescribed for chronic, long-term management of cardiovascular conditions.


Q: How does Arbloc affect someone's ability to drive or operate machinery?

The product information states that side effects of Arbloc, particularly common ones such as dizziness and somnolence (sleepiness), may affect the ability to operate complex or heavy machinery or to drive.


Q: Is Arbloc commonly prescribed for children?

Losartan potassium is officially indicated for the treatment of high blood pressure in pediatric patients aged 6 years and older. The safety and effectiveness have not been established in children younger than six years old.


Q: Is it true that Arbloc is a relatively new drug?

The active ingredient, Losartan, was first approved for use as a tablet in the mid-1990s. While it is not a recent discovery, its use marks it as an established and essential therapy in cardiovascular health.


Q: Are there specific times of day Arbloc is usually taken?

The medicine is intended to be taken once per day. Official instructions state that for therapeutic consistency, it is recommended to take the dose at approximately the same time each day.


Q: Are there any official warnings about taking Arbloc with grapefruit?

Some non-official reports indicate that consuming grapefruit may increase the absorption of the active ingredient, Losartan.


Q: What official health bodies have approved Arbloc?

The official documentation and clinical trial data for Arbloc are referenced by major global health agencies. Approving bodies cited in these documents include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: Can Arbloc affect fertility?

Preclinical data gathered from animal studies indicate that the active ingredient, Losartan, has shown potential to damage fertility or cause harm to the unborn child.


Q: What are the general patient expectations when starting Arbloc?

General expectations described in the official documents include taking the medicine once daily, and that the full therapeutic effect may take 3 to 6 weeks to become apparent. Common side effects such as dizziness and fatigue may occur.


Q: Does Arbloc have a black box warning in the US?

Yes, the official U.S. prescribing information includes a Boxed Warning regarding fetal toxicity. This is the highest level of warning and states that the drug can cause injury and death to the developing fetus when used during the second and third trimesters.

How should Arbloc be stored and disposed of?

Storage and Disposal Requirements

Arbloc (losartan potassium tablets) must be stored strictly according to regulatory labeling to maintain product stability and safety.

Storage Conditions

The tablets require storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from excess heat, light, and moisture, and must not be frozen. Keep the medication in its original, tightly closed container and store it out of the sight and reach of children.

Disposal Instructions

Expired or unneeded Arbloc should not be disposed of in household trash or flushed down the toilet. All unused product must be discarded in accordance with local authority and national regulations for pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arbloc found in:

A-Z Index: